Business
Medovex Corporation Closes Financing for a Total $7.2M Under Existing Securities Purchase Agreement
Medovex Corporation Closes Financing for a Total $7.2M Under Existing Securities Purchase Agreement.
About this update from Innoveren Scientific Inc.
[{"type":"text","content":"\nALPHARETTA, Ga., April 08, 2019 (GLOBE NEWSWIRE) -- Medovex Corporation (OTCQB: MDVX) (“Medovex” or the “Company”) today announced that on April 1, 2019, the Company entered into a securities purchase agreement with five purchasers pursuant to which the five purchasers invested in the Company an aggregate amount of $575,000.\n The closing date, extended to April 1, 2019 since March 31, 2019 was a Sunday, brings the aggregate amount of capital raised in this offering to $7,200,000. Previously on March 11, 2019, the Company entered into a securities purchase agreement with eight purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $1,250,000. Pursuant to the agreement, the Company increased the maximum offering size from $6,000,000 to $8,000,000 On February 6, 2019, the Company entered into a securities purchase agreement with four purchasers pursuant to which the four purchasers invested in the Company an aggregate amount of $475,000. Prior to that, the Company announced on January 18, 2019, it had entered into a securities purchase agreement with six purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,900,000. Prior to that on January 8, 2019, the Company announced it had entered into a securities purchase agreement with four purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,000,000, with $1,800,000 in cash and $200,000 by cancellation of debt. \"I’m pleased to announce the closing of this financing for an aggregate amount of $7,200,000. We continue to be grateful for the strong support of those who have invested in us in the past, and who continue to invest in our collective future. We continue to expect that many of these investors have the potential to bring value well beyond just traditional capital contributions,” said William “Bill” Horne, Medovex CEO and Chairman. The Company originally offered a minimum of $1,000,000 and a maximum of $6,000,000, subsequently increased to a maximum of $8,000,000, of units at a price of $50,000 per unit until the earlier of the closing of the subscription of the maximum amount and originally February 28, 2019, subsequently extended to March 31, 2019, (extended to April 1, 2019 since March 31, 2019 was a Sunday) subject...